Vis enkel innførsel

dc.contributor.authorBreeur, Marie
dc.contributor.authorFerrari, Pietro
dc.contributor.authorDossus, Laure
dc.contributor.authorJenab, Mazda
dc.contributor.authorJohansson, Mattias
dc.contributor.authorRinaldi, Sabina
dc.contributor.authorTravis, Ruth C.
dc.contributor.authorHis, Mathilde
dc.contributor.authorKey, Tim J.
dc.contributor.authorSchmidt, Julie A.
dc.contributor.authorOvervad, Kim
dc.contributor.authorTjønneland, Anne
dc.contributor.authorKyrø, Cecilie
dc.contributor.authorRothwell, Joseph A.
dc.contributor.authorLaouali, Nasser
dc.contributor.authorSeveri, Gianluca
dc.contributor.authorKaaks, Rudolf
dc.contributor.authorKatzke, Verena
dc.contributor.authorSchulze, Matthias B.
dc.contributor.authorEichelmann, Fabian
dc.contributor.authorPalli, Domenico
dc.contributor.authorGrioni, Sara
dc.contributor.authorPanico, Salvatore
dc.contributor.authorTumino, Rosario
dc.contributor.authorSacerdote, Carlotta
dc.contributor.authorBueno-de-Mesquita, Bas
dc.contributor.authorOlsen, Karina Standahl
dc.contributor.authorSandanger, Torkjel M
dc.contributor.authorNøst, Therese Haugdahl
dc.contributor.authorQuirós, J. Ramón
dc.contributor.authorBonet, Catalina
dc.contributor.authorBarranco, Miguel Rodríguez
dc.contributor.authorChirlaque, María-Dolores
dc.contributor.authorArdanaz, Eva
dc.contributor.authorSandsveden, Malte
dc.contributor.authorManjer, Jonas
dc.contributor.authorVidman, Linda
dc.contributor.authorRentoft, Matilda
dc.contributor.authorMuller, David
dc.contributor.authorTsilidis, Kostas
dc.contributor.authorHeath, Alicia K.
dc.contributor.authorKeun, Hector
dc.contributor.authorAdamski, Jerzy
dc.contributor.authorKeski-Rahkonen, Pekka
dc.contributor.authorScalbert, Augustin
dc.contributor.authorGunter, Marc J.
dc.contributor.authorViallon, Vivian
dc.date.accessioned2022-12-27T12:48:21Z
dc.date.available2022-12-27T12:48:21Z
dc.date.issued2022-10-19
dc.description.abstractBackground - Epidemiological studies of associations between metabolites and cancer risk have typically focused on specific cancer types separately. Here, we designed a multivariate pan-cancer analysis to identify metabolites potentially associated with multiple cancer types, while also allowing the investigation of cancer type-specific associations.<p> <p>Methods - We analysed targeted metabolomics data available for 5828 matched case-control pairs from cancer-specific case-control studies on breast, colorectal, endometrial, gallbladder, kidney, localized and advanced prostate cancer, and hepatocellular carcinoma nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. From pre-diagnostic blood levels of an initial set of 117 metabolites, 33 cluster representatives of strongly correlated metabolites and 17 single metabolites were derived by hierarchical clustering. The mutually adjusted associations of the resulting 50 metabolites with cancer risk were examined in penalized conditional logistic regression models adjusted for body mass index, using the data-shared lasso penalty.<p> <p>Results - Out of the 50 studied metabolites, (i) six were inversely associated with the risk of most cancer types: glutamine, butyrylcarnitine, lysophosphatidylcholine a C18:2, and three clusters of phosphatidylcholines (PCs); (ii) three were positively associated with most cancer types: proline, decanoylcarnitine, and one cluster of PCs; and (iii) 10 were specifically associated with particular cancer types, including histidine that was inversely associated with colorectal cancer risk and one cluster of sphingomyelins that was inversely associated with risk of hepatocellular carcinoma and positively with endometrial cancer risk.<p> <p>Conclusions - These results could provide novel insights for the identification of pathways for cancer development, in particular those shared across different cancer types.en_US
dc.identifier.citationBreeur, Ferrari, Dossus, Jenab, Johansson, Rinaldi, Travis, His, Key, Schmidt, Overvad, Tjønneland, Kyrø, Rothwell, Laouali, Severi, Kaaks, Katzke, Schulze, Eichelmann, Palli, Grioni, Panico, Tumino, Sacerdote, Bueno-de-Mesquita, Olsen, Sandanger, Nøst, Quirós, Bonet, Barranco, Chirlaque, Ardanaz, Sandsveden, Manjer, Vidman, Rentoft, Muller, Tsilidis, Heath, Keun, Adamski, Keski-Rahkonen, Scalbert, Gunter, Viallon. Pan-cancer analysis of pre-diagnostic blood metabolite concentrations in the European Prospective Investigation into Cancer and Nutrition. BMC Medicine. 2022;20(1)en_US
dc.identifier.cristinIDFRIDAID 2082154
dc.identifier.doi10.1186/s12916-022-02553-4
dc.identifier.issn1741-7015
dc.identifier.urihttps://hdl.handle.net/10037/27924
dc.language.isoengen_US
dc.publisherBMCen_US
dc.relation.journalBMC Medicine
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7-INFRASTRUCTURES/313010/Norway/BBMRI - Large Prospective Cohorts/BBMRI-LPC/en_US
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titlePan-cancer analysis of pre-diagnostic blood metabolite concentrations in the European Prospective Investigation into Cancer and Nutritionen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution 4.0 International (CC BY 4.0)
Med mindre det står noe annet, er denne innførselens lisens beskrevet som Attribution 4.0 International (CC BY 4.0)